Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunoprecise Antibodies Ltd
(NQ:
IPA
)
0.6501
-0.0199 (-2.97%)
Streaming Delayed Price
Updated: 11:29 AM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
65,185
Open
0.6500
Bid (Size)
0.6500 (78)
Ask (Size)
0.6700 (20)
Prev. Close
0.6700
Today's Range
0.6500 - 0.6800
52wk Range
0.5300 - 2.600
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
September 26, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
September 16, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Performance
YTD
-61.76%
-61.76%
1 Month
-15.16%
-15.16%
3 Month
-34.33%
-34.33%
6 Month
-57.23%
-57.23%
1 Year
-65.05%
-65.05%
More News
Read More
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
September 09, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Earnings Outlook For ImmunoPrecise Antibodies
March 13, 2024
Via
Benzinga
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 26, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
August 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
July 29, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
July 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
July 16, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
July 15, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
June 27, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
June 25, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
June 12, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
June 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
EXCLUSIVE: ImmunoPrecise Antibodies' Subsidiary Releases Software With Customizable Interface For AI-Driven Drug Discovery
June 10, 2024
Via
Benzinga
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
June 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
April 22, 2024
Via
ACCESSWIRE
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
April 12, 2024
Via
ACCESSWIRE
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
March 28, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications
March 28, 2024
Via
Benzinga
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
March 20, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024
March 14, 2024
Via
InvestorPlace
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
March 14, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Earnings Scheduled For March 14, 2024
March 14, 2024
Via
Benzinga
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
March 08, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
